RARECast

RARECast

By RARECastBusiness
Download on the App Store

RARECast episodes

  • When "Undiagnosed" Is Your Diagnosis
    Before most rare disease patients have a name to give their condition, they go on a diagnostic odyssey than can take years and usually involves multiple specialists. For some patients, the answer never comes. In the absence of a diagnosis, patients face significant challenges getting the care they need, reimbursed by insurers, or necessary accommodations from schools or employers. Ahead of Undiagnosed Disease Day, which takes place April 29, we spoke to Gina Szajnuk, executive director of the Rare and Undiagnosed Network and Matt Might, Director of the Hugh Kaul Personalized Medicine Institute at the University of Alabama at Birmingham School of Medicine. They discussed what it’s like to be undiagnosed, efforts to raise awareness about the plight of undiagnosed patients, and why “undiagnosed” is a diagnosis.
    25 min
  • The Decision to Get Tested for Huntington's Disease and How It Changed Seth Rotberg's Life
    Seth Rotberg grew up in the shadow of Huntington’s disease, a rare, genetic, neurodegenerative condition. Children of people with Huntington’s have a 50 percent chance of developing it themselves. When Rotberg was in college, he made the decision to get tested to see if he too would develop the disease. We spoke to Rotberg about his decision to get tested, why he largely kept the results to himself for two years, and what led him to become a patient advocate.
    27 min
  • Nonprofit Sees Need in Developing Gene Therapies for Inherited Eye Disesases
    For people with inherited retinal diseases, gene therapies carry the promise of potentially preventing and even curing blindness. But the small patient populations for with people these conditions make it difficult to attract commercial interests. Odylia Therapeutics, a recently unveiled nonprofit gene therapy developer, is hoping to bridge the gap between academic researchers and drug developers by conducting preclinical and early-stage clinical development on gene therapies for inherited eye diseases. We spoke to Scott Dorfman, co-founder and CEO of Odylia, about what drove the creation of the company, how it works as a nonprofit, and whether it may make sense to extend the model to carry these therapies to patients.
    23 min
  • Casting a Wider Net for Genetic Diseases
    While breakthroughs in the ability to diagnose newborns with genetic diseases continues to expand in scope and fall in cost, the extent of newborn screening varies state-by-state. Nevertheless, the improving affordability of newborn screening is expanding access to these tests for parents seeking them. We spoke to Eric Schadt, CEO of Sema4, about the changing landscape for newborn screening, the company’s Natalis test, and how far off we are from routine screening of newborns with comprehensive genetic sequencing.
    24 min
  • Corbus Seeks to Quiet the Immune System in Chronic Conditions
    Inflammation is a complex biological response to potential threats. But sometimes when the immune system is triggered, its fails to resolve, and unwanted damage ensues. Many inflammatory diseases result from a flooding of signals to activate the immune system without adequate off-signals to resolve it. Corbus Pharmaceuticals lead candidate lenabasum targets the immune system off-switch. The company is in late-stage testing of the experimental therapy for the rare condition systemic sclerosis. We spoke to Yuval Cohen, CEO of Corbus, about the workings of the immune system, what lenabasum does, and why it may have use in a broad number of chronic inflammatory and fibrotic conditions.
    21 min
  • Addressing the Challenges of Rare Disease Drug Development
    Developing therapeutics for rare diseases can be challenging, and not just because of the small patient populations. Often the progression of a disease is not well understood, the patient population can be heterogenous, and the development of objective and meaningful endpoints for a trial can be difficult. We spoke to Ralf Rosskamp, chief medical officer of Dicerna, about how his company has navigated the various challenges in its effort to develop a treatment for a rare liver disorders, how it finds patients, and how it determines endpoints.
    28 min
  • Giving Voice to Patients at the FDA
    Nearly a year ago, more than 400 members of spinal muscular atrophy community along with industry, clinicians, and researchers convened a patient-focused drug development meeting with the U.S. Food and Drug Administration to give voice to patient views on the impact the rare condition has on their lives and their priorities for treatments. CureSMA, which organized the event, recently issued its Voice of the Patient report based on the meeting. We spoke to Rosángel Cruz, associate research director of clinical affairs for CureSMA about the report, how it is being used, and what other patient groups could learn from CureSMA’s experience.
    25 min
  • Finding a Rare Friend
    Makayla Allison’s daughter Lily was born with a rare genetic disease with many symptoms, complex challenges, and no diagnosis. As she grew older, one of the things she told her mother she wanted was to have friends like her, ones with the same health issues. That led Allison to create Someone 1 Like You, an online service that connects people with rare diseases with others with the same conditions. We spoke to Allison, founder and CEO of Some 1 Like You, about the genesis of the service, how it works, and why a diagnosis isn’t necessary to finding a connection.
    21 min
  • Why a Sports Physical May Trigger a Doctor to Think About a Rare Diagnosis
    Marfan syndrome is a genetic disorder that affects the body’s connective tissue. Though people with the disease can look long and lean and ideal for certain sports, strenuous activity can be dangerous because the disease can cause enlargement of the aorta and lead to sudden death under extreme exertion. For Marfan Syndrome Awareness Month we spoke to Alan Braverman, professor of medicine at Washington University, cardiologist at Barnes-Jewish Hospital and a member the professional advisory board and board of directors of The Marfan Foundation, about the disease, how it’s diagnosed, and what patients with the condition can do to lead a long and healthy life.
    20 min
  • UPenn's Orphan Disease Center Takes a Rare Approach
    Rare disease centers at academic institutions are usually places that focus on early-stage research of faculty members, but the Orphan Disease Center at the University of Pennsylvania’s Perelman School of Medicine takes a multidimensional approach to address the needs or the rare disease community. In addition to conducting its own research, the center collaborates with both pharmaceutical companies and patient groups, makes grants to support external research, and helps patient groups and families find new researchers and helps guide them to develop essential tools to work on a specific disease. We spoke to Ashley Winslow, senior director of portfolio development at the center, about its work, how it has evolved from its origins, and how it leverages the work it does through collaboration.
    22 min

About RARECast

From the publisher's feed

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.